• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

A Day Never to Forget, Red-Hot Debt Market, Moderna Marches On, Biden Thumbs Up

Plus, Zscaler largely delivers for its owners with its latest results.
By STEPHEN GUILFOYLE
Sep 10, 2021 | 07:13 AM EDT
Stocks quotes in this article: XLRE, XLV, XLF, PFE, BNTX, MRNA, ZS, KR

Twenty Years Ago

My briefcase stands still

Exactly where I placed it down that day

Untouched for two decades, covered now with years of dust

Inside, a newspaper, some pens and memories of those that went away

I still see their faces

I think of them that way

Alvin's quirky smile

Bing's singing voice

Elvin nervously working hard

Tommy's quick auction market brain

Tough not to recall

Something positive about them all

My brain now grows old

My beard now grows gray

Ahead lies my destiny

Twelve faces own my yesterday

Why we must do this each year

When it brings back for us such woe

So that we always keep fresh

Memories of those lost twenty years ago

Never Forgive

Never Forget

23 October 1983

11 September 2001

Marketplace

First off, for peripheral market followers, equities were probably not nearly as weak on Thursday as you think. Sure, the S&P 500 gave up 0.5%, the Nasdaq Composite 0,3%. Sure, the Dow Transports gave up 1.1% on weakness across the rails, truckers and delivery services despite surprising strength in the airlines. Sure, eight of the 11 Sector Select SPDR ETFs closed in the red, but please note that the four defensive sectors took the bottom four rungs on the daily performance tables, with Real Estate (XLRE) and Health Care (XLV) much weaker than everything else. Big pharma, of course, came under pressure as the Biden administration unveiled a plan to reduce drug prices.

A flip of the coin reveals that cyclical sectors lit what seemed to be a dark road, as Financials (XLF) led the markets on a day where sharp demand for both U.S. sovereign and corporate debt constricted yield spreads. Just a by the way... some of those yields have been on the rise overnight. Investors may be mildly surprised to learn that on what was a supposed "down" day that winners beat losers by a few hundred issues at the Nasdaq, while losers just barely edged winners at the NYSE. However, advancing volume beat declining volume by more than 4 to 3 downtown and by an overwhelming 2 to 1 up at Times Square. Trading volumes, though lighter than on Wednesday, remained elevated in comparison to recent norms.

Another word on debt markets: Treasury once again saw good demand from abroad as $24 billion of 30-year bonds hit auction on top of the $38 billion of 10-year notes sold off earlier in the week. Bid to cover for the long bond was an impressive 2.5, while Indirect bidders took down a truly remarkable 69.6% of the issue. In addition, another 14 investment-grade borrowers tapped corporate debt markets on Thursday, bringing the number of investment-grade issuers up to 52 over three days, and the total amount borrowed across these 52 firms up to more than $75 billion. The first week of September is typically a hot week for new corporate debt, but this week is indeed hotter than is typical.

Friday Morning

U.S. equity index futures have been rather strong all night, as have for the most part both Asian and European equity markets themselves. We know this is not in response to the European Central Bank's decision to "moderately" reduce the pace of its Pandemic Emergency Purchase Program (PEPP), despite ECB President Christine Lagarde's assurances that "the lady isn't tapering." Yeah, that wasn't too weird.

Rather, credit for an off-hours northerly turn for equites, as well as a slightly southerly turn for the already mentioned U.S. debt markets is going (at least by this author) to two things President Biden did on Thursday evening. First, the president got more aggressive in trying to tackle the pandemic. Second, President Biden placed a phone call to President Xi of China supposedly to touch base on areas of mutual concern. Chinese state TV referred to the call as "in-depth" and "extensively strategic." Hey, the more contact there, the better. Better than playing the Navy's version of cat and mouse in the Taiwan Strait or the East China Sea.

Now, about the president's new plan in addressing COVID: The president is directing executive branch federal employees and contractors to be vaccinated against the virus while removing the option to test regularly and mask up. The president also has directed the Department of Labor to finalize plans requiring all private sector employers of 100 employees or more to mandate vaccination across their payrolls, or at least require weekly testing for those still reluctant. Between the two directives, about two-thirds of the U.S. labor force is impacted. The administration is also encouraging all sports and entertainment venues to require customers to show proof of vaccination or a very recent negative test.

Many business leaders are seeing these directives as well as the recent full approval of the Pfizer (PFE) /BioNTech (BNTX) vaccine and expected (shortly?) full approval for the Moderna (MRNA) jabs as potential game changers for the U.S. economy as hopes soar that this allows more businesses to return to more elevated levels of production and more laborers to seek employment. That would still leave those still ineligible for vaccination (young children) and those that care for them on the sidelines.

I try to be fair, and apolitical. Most readers know I have no real allegiance to either major political party -- indeed, I think they both stink -- but that I lean conservative certainly on fiscal and sometimes political matters. That said, I feel if one finds themselves consistently on the same side of the aisle on each and every issue that one probably needs to look themselves in the mirror. What I am getting at is that I have been hard on President Biden and his cabinet for the way we left Afghanistan. I still think a resignation or two is probably appropriate in the wake of that fiasco. I think the president did the right thing last night in regard to vaccination as well as in regard to reaching out to President Xi.

Many folks are still terrified of these vaccines. I know the side effects are different for everyone, but I would line up every five months for the rest of my life to get a booster if that meant I never had to go through COVID again. In my experience, the impacts of the virus itself and the side effects of the vaccine have not been comparable.

On Moderna

On Thursday, the stock of Moderna ran more than $33, or 7.8%, despite broad weakness in both Biotechs and Pharmaceuticals. Thursday was Moderna's Research and Development presentation day. It revealed a number of "improved" vaccines it currently is working on. It's working on three different vaccine combinations specifically targeting the Beta and Delta variants of the SARS-CoV-2 coronavirus. A fourth is a combination of the firm's original vaccine, mRNA-1273, with specific Beta variant fighting properties.

The company is awaiting full Food and Drug Administration (FDA) approval for its original COVID vaccine as well as Emergency Use Authorization for booster shots. In addition, it has enrolled 4,000 participants in a Phase 2 study of the original vaccine in 6- to 12-year-old children.

What I found interesting as someone who will likely end up receiving some kind of shot annually was the announcement that Moderna is working on a new vaccine candidate, mRNA-1073, that is intended to be a one-jab dose that combines a COVID vaccine with a flu shot. How wonderful would that be if it works? I told you back in the early days of the pandemic that I have great faith in the future of messenger RNA technology. I don't know if I will live to see it, but I truly think this is at least the start of mankind's eradication of disease. Almost all disease. Period.

I remain long Moderna. My price target is infinity. Infinity and beyond.

Trading Note

Well, gang, we pretty much got everything we asked for when Zscaler (ZS) reported on Thursday night. Adjusted earnings beat. Revenue beat on growth of more than 56%. Billings up 70%. Deferred revenue up 71%. Fiscal first-quarter and full-year 2022 sales guidance above consensus. Only negative caveats? In-line guidance for current-quarter EPS and midpoint full-year EPS guidance about a penny below consensus. Otherwise, wonderful.

That's why I once again expect to take profits today. This time, it will be only a partial. I have learned that lesson the hard way. Again. Have a good weekend, kids. God bless.

Economics (All Times Eastern)

08:30 - PPI (Aug): Expecting 1.7% y/y, Last 7.8% y/y.

08:30 - Core PPI (Aug): Expecting 1.6% y/y, Last 6.2% y/y.

10:00 - Wholesale Inventories (July-rev): Falshed 0.6% m/m.

13:00 - Baker Hughes Oil Rig Count (Weekly): Last 394.

The Fed (All Times Eastern)

09:00 - Speaker: Cleveland Fed Pres. Loretta Mester.

Today's Earnings Highlights (Consensus EPS Expectations)

Before the Open: (KR) (.64)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Guilfoyle was long PFE, MRNA and ZS equity.

TAGS: Bonds | Corporate Bonds | Drug Approvals | ETFs | Investing | Politics | Stocks | Treasury Bonds | Biotechnology | Pharmaceuticals | Real Money | Coronavirus

More from Stocks

The Chasing Slows on Wall Street

James "Rev Shark" DePorre
Mar 24, 2023 4:34 PM EDT

After Deutsche Bank shakes up investors, market cools a bit, which might be a healthy development.

Stay Away From These Types of Stocks, They're Radioactive

Jim Collins
Mar 24, 2023 2:35 PM EDT

Here's what you're better off buying. I certainly have.

GE Looks Poised for a Pullback: How to Trade It Now

Bruce Kamich
Mar 24, 2023 1:45 PM EDT

The shares stopped short of my price targets.

It's Not Whether the Next Shoe Will Drop, But Where and When

Bret Jensen
Mar 24, 2023 11:30 AM EDT

A few months of anxiety likely lies ahead of us, and caution remains the watchword of the day.

The Good, Bad and Ugly: What's Happening and What Investors Need to Do

Stephen Guilfoyle
Mar 24, 2023 10:45 AM EDT

Right now I have more in cash, or equivalents, than in equities. Ever hear of a Wall Street guy saying that before?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • 05:00 PM EDT CHRIS VERSACE

    AAP Podcast on the Fed Decision!

    Listen here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login